Outpace Bio Website, Blog & Press Pages

Outpace Bio Website, Blog & Press Pages - aVenture

Outpace Bio - Library

outpacebio.comCrawled Oct 15, 2026

Press

1 page

News/news
Latest updates on AI-powered cell therapy development, clinical trials, partnerships, and breakthrough research in solid tumor treatment.

Homepage

1 page

Homepage/
Outpace Bio designs smarter cell therapies. OUTSPACER, OUTSMART, OUTLAST, OUTSAFE, OUTDRIVE and OUTMATCH technologies make engineered cells more effective, safer and scalable against cancer.

Privacy

1 page

Privacy Policy/resources/privacy-policy
Outpace Bio's Privacy Policy describes how it collects, uses, and protects personal data of website visitors and partners.

Terms & Conditions

2 pages

Terms of Use/resources/terms-of-use
Outpace Bio's Terms of Use outline conditions for accessing and using its website and biotechnology services.
Unsolicited Content/resources/unsolicited-content-policy
Understand Outpace Bio's policy regarding unsolicited submissions of ideas, research proposals, and biotechnology concepts.

Coverage

6 items

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Developmentglobenewswire.com/fr/news-release/2024/08/01/2922848/0/en/outpace-bio-announces-144m-oversubscribed-series-b-financing-to-advance-ai-powered-cell-therapies-into-clinical-development.html
Outpace Bio raises $144 million in an oversubscribed Series B financing led by RA Capital Management, bringing its total capital raised to approximately $200 million. The company plans to use the funding to advance programmed T cell product candidates toward early clinical proof-of-concept in solid tumors.
Aug 2024 · GlobeNewswireNews article
Protein design startup Outpace lands $144M to test treatments that target solid tumorsgeekwire.com/2024/protein-design-startup-outpace-lands-144m-to-test-treatments-that-target-solid-tumors/
Outpace Bio raises $144 million in Series B funding led by RA Capital Management to test its protein-designed T cell treatment for solid tumors in a clinical setting. The round brings the startup’s total funding to $200 million.
Aug 2024 · GeekWireNews article
outpace-biogithub.com/outpace-bio
GitHubRepository owner
Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub & Collaborations with Leading Experts in Protein Design & Cancer Immunotherapybiospace.com/outpace-bio-expands-seattle-presence-with-cell-therapy-research-hub-and-collaborations-with-leading-experts-in-protein-design-and-cancer-immunotherapy
Outpace Bio opens a 23,000-square-foot research facility at Seattle’s Dexter Yard, expanding its local presence. The company also extends research collaborations with David Baker at the UW Institute for Protein Design and Stan Riddell at Fred Hutchinson Cancer Center, focused on protein design and cancer immunotherapy.
May 2023 · BioSpaceNews article